IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-31379-0.html
   My bibliography  Save this article

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial

Author

Listed:
  • Nawal Al Kaabi

    (Sheikh Khalifa Medical City, SEHA
    Khalifa University)

  • Yun Kai Yang

    (China National Biotec Group Company Limited)

  • Li Fang Du

    (National Vaccine and Serum Institute (NVSI)
    National Engineering Center for New Vaccine Research)

  • Ke Xu

    (Chinese Center for Disease Control and Prevention (China CDC))

  • Shuai Shao

    (National Vaccine and Serum Institute (NVSI)
    National Engineering Center for New Vaccine Research)

  • Yu Liang

    (National Vaccine and Serum Institute (NVSI)
    National Engineering Center for New Vaccine Research)

  • Yun Kang

    (National Engineering Center for New Vaccine Research
    National Vaccine and Serum Institute (NVSI))

  • Ji Guo Su

    (National Vaccine and Serum Institute (NVSI)
    National Engineering Center for New Vaccine Research)

  • Jing Zhang

    (National Vaccine and Serum Institute (NVSI)
    National Engineering Center for New Vaccine Research)

  • Tian Yang

    (China National Biotec Group Company Limited)

  • Salah Hussein

    (Sheikh Khalifa Medical City, SEHA)

  • Mohamed Saif ElDein

    (Sheikh Khalifa Medical City, SEHA)

  • Sen Sen Yang

    (National Engineering Center for New Vaccine Research
    National Vaccine and Serum Institute (NVSI))

  • Wenwen Lei

    (Chinese Center for Disease Control and Prevention (China CDC))

  • Xue Jun Gao

    (Lanzhou Institute of Biological Products Company Limited)

  • Zhiwei Jiang

    (Beijing Key Tech Statistical Consulting Co., Ltd)

  • Xiangfeng Cong

    (National Engineering Center for New Vaccine Research
    National Vaccine and Serum Institute (NVSI))

  • Yao Tan

    (National Engineering Center for New Vaccine Research
    National Vaccine and Serum Institute (NVSI))

  • Hui Wang

    (Beijing Institute of Biological Products Company Limited)

  • Meng Li

    (China National Biotec Group Company Limited)

  • Hanadi Mekki Mekki

    (Union 71)

  • Walid Zaher

    (G42 Healthcare)

  • Sally Mahmoud

    (G42 Healthcare)

  • Xue Zhang

    (China National Biotec Group Company Limited)

  • Chang Qu

    (China National Biotec Group Company Limited)

  • Dan Ying Liu

    (China National Biotec Group Company Limited)

  • Jing Zhang

    (Chinese Center for Disease Control and Prevention (China CDC))

  • Mengjie Yang

    (Chinese Center for Disease Control and Prevention (China CDC))

  • Islam Eltantawy

    (G42 Healthcare)

  • Jun Wei Hou

    (National Vaccine and Serum Institute (NVSI)
    National Engineering Center for New Vaccine Research)

  • Ze Hua Lei

    (National Vaccine and Serum Institute (NVSI)
    National Engineering Center for New Vaccine Research)

  • Peng Xiao

    (G42 Healthcare)

  • Zhao Nian Wang

    (China National Biotec Group Company Limited)

  • Jin Liang Yin

    (China National Biotec Group Company Limited)

  • Xiao Yan Mao

    (Lanzhou Institute of Biological Products Company Limited)

  • Jin Zhang

    (Beijing Institute of Biological Products Company Limited)

  • Liang Qu

    (China National Biotec Group Company Limited)

  • Yun Tao Zhang

    (China National Biotec Group Company Limited)

  • Xiao Ming Yang

    (China National Biotec Group Company Limited)

  • Guizhen Wu

    (Chinese Center for Disease Control and Prevention (China CDC))

  • Qi Ming Li

    (National Vaccine and Serum Institute (NVSI)
    National Engineering Center for New Vaccine Research)

Abstract

NVSI-06-08 is a potential broad-spectrum recombinant COVID-19 vaccine that integrates the antigens from multiple SARS-CoV-2 strains into a single immunogen. Here, we evaluate the safety and immunogenicity of NVSI-06-08 as a heterologous booster dose in BBIBP-CorV recipients in a randomized, double-blind, controlled, phase 2 trial conducted in the United Arab Emirates (NCT05069129). Three groups of healthy adults over 18 years of age (600 participants per group) who have administered two doses of BBIBP-CorV 4-6-month, 7-9-month and >9-month earlier, respectively, are randomized 1:1 to receive either a homologous booster of BBIBP-CorV or a heterologous booster of NVSI-06-08. The incidence of adverse reactions is low, and the overall safety profile is quite similar between two booster regimens. Both Neutralizing and IgG antibodies elicited by NVSI-06-08 booster are significantly higher than those by BBIBP-CorV booster against not only SARS-CoV-2 prototype strain but also multiple variants of concerns (VOCs). Especially, the neutralizing antibody GMT against Omicron variant induced by heterologous NVSI-06-08 booster reaches 367.67, which is substantially greater than that boosted by BBIBP-CorV (GMT: 45.03). In summary, NVSI-06-08 is safe and immunogenic as a booster dose following two doses of BBIBP-CorV, which is immunogenically superior to the homologous boost with another dose of BBIBP-CorV.

Suggested Citation

  • Nawal Al Kaabi & Yun Kai Yang & Li Fang Du & Ke Xu & Shuai Shao & Yu Liang & Yun Kang & Ji Guo Su & Jing Zhang & Tian Yang & Salah Hussein & Mohamed Saif ElDein & Sen Sen Yang & Wenwen Lei & Xue Jun G, 2022. "Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31379-0
    DOI: 10.1038/s41467-022-31379-0
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-31379-0
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-31379-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Sandile Cele & Laurelle Jackson & David S. Khoury & Khadija Khan & Thandeka Moyo-Gwete & Houriiyah Tegally & James Emmanuel San & Deborah Cromer & Cathrine Scheepers & Daniel G. Amoako & Farina Karim , 2022. "Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization," Nature, Nature, vol. 602(7898), pages 654-656, February.
    2. Lihong Liu & Sho Iketani & Yicheng Guo & Jasper F.-W. Chan & Maple Wang & Liyuan Liu & Yang Luo & Hin Chu & Yiming Huang & Manoj S. Nair & Jian Yu & Kenn K.-H. Chik & Terrence T.-T. Yuen & Chaemin Yoo, 2022. "Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2," Nature, Nature, vol. 602(7898), pages 676-681, February.
    3. Xiaoqi Yu & Dong Wei & Wenxin Xu & Chuanmiao Liu & Wentian Guo & Xinxin Li & Wei Tan & Leshan Liu & Xinxin Zhang & Jieming Qu & Zhitao Yang & Erzhen Chen, 2022. "Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jie Deng & Yirui Ma & Qiao Liu & Min Du & Min Liu & Jue Liu, 2022. "Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis," IJERPH, MDPI, vol. 19(17), pages 1-17, August.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Tomohiro Takano & Takashi Sato & Ryutaro Kotaki & Saya Moriyama & Shuetsu Fukushi & Masahiro Shinoda & Kiyomi Kabasawa & Nagashige Shimada & Mio Kousaka & Yu Adachi & Taishi Onodera & Kazutaka Terahar, 2023. "Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    2. Cai He & Jingyun Yang & Weiqi Hong & Zimin Chen & Dandan Peng & Hong Lei & Aqu Alu & Xuemei He & Zhenfei Bi & Xiaohua Jiang & Guowen Jia & Yun Yang & Yanan Zhou & Wenhai Yu & Cong Tang & Qing Huang & , 2022. "A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    3. Hassen Kared & Asia-Sophia Wolf & Amin Alirezaylavasani & Anthony Ravussin & Guri Solum & Trung The Tran & Fridtjof Lund-Johansen & John Torgils Vaage & Lise Sofie Nissen-Meyer & Unni C. Nygaard & Ola, 2022. "Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    4. Rebecca Urschel & Saskia Bronder & Verena Klemis & Stefanie Marx & Franziska Hielscher & Amina Abu-Omar & Candida Guckelmus & Sophie Schneitler & Christina Baum & Sören L. Becker & Barbara C. Gärtner , 2024. "SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    5. Rafael R. G. Machado & Jordyn L. Walker & Dionna Scharton & Grace H. Rafael & Brooke M. Mitchell & Rachel A. Reyna & William M. Souza & Jianying Liu & David H. Walker & Jessica A. Plante & Kenneth S. , 2023. "Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    6. Taha Y. Taha & Irene P. Chen & Jennifer M. Hayashi & Takako Tabata & Keith Walcott & Gabriella R. Kimmerly & Abdullah M. Syed & Alison Ciling & Rahul K. Suryawanshi & Hannah S. Martin & Bryan H. Bach , 2023. "Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    7. Wenkai Han & Ningning Chen & Xinzhou Xu & Adil Sahil & Juexiao Zhou & Zhongxiao Li & Huawen Zhong & Elva Gao & Ruochi Zhang & Yu Wang & Shiwei Sun & Peter Pak-Hang Cheung & Xin Gao, 2023. "Predicting the antigenic evolution of SARS-COV-2 with deep learning," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    8. Seoryeong Park & Jaewon Choi & Yonghee Lee & Jinsung Noh & Namphil Kim & JinAh Lee & Geummi Cho & Sujeong Kim & Duck Kyun Yoo & Chang Kyung Kang & Pyoeng Gyun Choe & Nam Joong Kim & Wan Beom Park & Se, 2024. "An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation," Nature Communications, Nature, vol. 15(1), pages 1-9, December.
    9. Lifeng Zhang & Roy E. Welsch & Zhi Cao, 2022. "The Transmission, Infection Prevention, and Control during the COVID-19 Pandemic in China: A Retrospective Study," IJERPH, MDPI, vol. 19(5), pages 1-15, March.
    10. Yin-Feng Kang & Cong Sun & Jing Sun & Chu Xie & Zhen Zhuang & Hui-Qin Xu & Zheng Liu & Yi-Hao Liu & Sui Peng & Run-Yu Yuan & Jin-Cun Zhao & Mu-Sheng Zeng, 2022. "Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    11. Meriem Bekliz & Kenneth Adea & Pauline Vetter & Christiane S. Eberhardt & Krisztina Hosszu-Fellous & Diem-Lan Vu & Olha Puhach & Manel Essaidi-Laziosi & Sophie Waldvogel-Abramowski & Caroline Stephan , 2022. "Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    12. Haofeng Wang & Qi Yang & Xiaoce Liu & Zili Xu & Maolin Shao & Dongxu Li & Yinkai Duan & Jielin Tang & Xianqiang Yu & Yumin Zhang & Aihua Hao & Yajie Wang & Jie Chen & Chenghao Zhu & Luke Guddat & Hong, 2023. "Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    13. Alejandro Jara & Cristobal Cuadrado & Eduardo A. Undurraga & Christian García & Manuel Nájera & María Paz Bertoglia & Verónica Vergara & Jorge Fernández & Heriberto García-Escorza & Rafael Araos, 2023. "Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile," Nature Communications, Nature, vol. 14(1), pages 1-7, December.
    14. Xiaolei Wang & Terrence Tsz-Tai Yuen & Ying Dou & Jingchu Hu & Renhao Li & Zheng Zeng & Xuansheng Lin & Huarui Gong & Celia Hoi-Ching Chan & Chaemin Yoon & Huiping Shuai & Deborah Tip-Yin Ho & Ivan Fa, 2023. "Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    15. Alief Moulana & Thomas Dupic & Angela M. Phillips & Jeffrey Chang & Serafina Nieves & Anne A. Roffler & Allison J. Greaney & Tyler N. Starr & Jesse D. Bloom & Michael M. Desai, 2022. "Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    16. Laurent Renia & Yun Shan Goh & Angeline Rouers & Nina Bert & Wan Ni Chia & Jean-Marc Chavatte & Siew‐Wai Fong & Zi Wei Chang & Nicole Ziyi Zhuo & Matthew Zirui Tay & Yi-Hao Chan & Chee Wah Tan & Nicho, 2022. "Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    17. G. Tuba Barut & Nico Joel Halwe & Adriano Taddeo & Jenna N. Kelly & Jacob Schön & Nadine Ebert & Lorenz Ulrich & Christelle Devisme & Silvio Steiner & Bettina Salome Trüeb & Bernd Hoffmann & Inês Bere, 2022. "The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    18. Xuanming Guo & Jianli Cao & Jian-Piao Cai & Jiayan Wu & Jiangang Huang & Pallavi Asthana & Sheung Kin Ken Wong & Zi-Wei Ye & Susma Gurung & Yijing Zhang & Sheng Wang & Zening Wang & Xin Ge & Hiu Yee K, 2022. "Control of SARS-CoV-2 infection by MT1-MMP-mediated shedding of ACE2," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    19. Lei Wang & Zhiwei Wu & Zhifang Ying & Minjie Li & Yuansheng Hu & Qun Shu & Jing Li & Huixian Wang & Hengming Zhang & Wenbin Jiao & Lin Wang & Yuliang Zhao & Qiang Gao, 2022. "Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    20. Nina Breinholt Stærke & Joanne Reekie & Henrik Nielsen & Thomas Benfield & Lothar Wiese & Lene Surland Knudsen & Mette Brouw Iversen & Kasper Iversen & Kamille Fogh & Jacob Bodilsen & Maria Ruwald Juh, 2022. "Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections," Nature Communications, Nature, vol. 13(1), pages 1-8, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31379-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.